

Teglarinad chloride

Chemical Properties

CAS No. : 432037-57-5


Formula: C30H43Cl2N5O8

Molecular Weight: 672.6

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Teglarinad chloride (GMX-1777 chloride) is a potent inhibitor of NAMPT, the precursor of GMX1778. Teglarinad chloride has antitumor activity and acts by interfering with DNA repair and inhibiting angiogenesis.
Targets(IC50)	NAMPT
In vivo	In the IM-9 model, small-cell lung cancer (SHP-77) model, and colon carcinoma (HCT-116) model, GMX1777 (75 mg/kg; 24 h intravenous infusion) induces tumor regression [2]. For both FaDu and C666-1 tumors in vivo, GMX1777 (50-100 mg/kg/day, intramuscular for 5 days), with or without local tumor radiotherapy, proves to be effective [1]. Upon intravenous infusion (25-400 mg/kg; 24 h), GMX1777 is rapidly converted to GMX1778 in the plasma of mice, with a half-life of GMX1777 less than 0.7 h [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.4868 mL	7.4338 mL	14.8677 mL
5 mM	0.2974 mL	1.4868 mL	2.9735 mL
10 mM	0.1487 mL	0.7434 mL	1.4868 mL
50 mM	0.0297 mL	0.1487 mL	0.2974 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Beauparlant P, et, al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. *Anticancer Drugs*. 2009 Jun;20(5):346-54.

Kato H, et, al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. *Clin Cancer Res*. 2010 Feb 1;16(3):898-911.

Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougard AV, Björkling F, Jensen PB, Nielsen SJ, Sehested M. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. *BMC Cancer*. 2010 Dec 12;10:677. doi: 10.1186/1471-2407-10-677. PubMed PMID: 21144000; PubMed Central PMCID: PMC3019212.

Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. *Cancer Biol Ther*. 2010 Jul 15;10(2):119-25. doi: 10.4161/cbt.10.2.12581. Epub 2010 Jul 3. Review. PubMed PMID: 20647743.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481